Irvine, Calif.-based CalbaTech said the acquisition would strengthen its position in the life sciences market by adding a large-scale distribution operation to sell products from its research reagents division. That division includes its MoleculA unit and the recently acquired K-D Medical.
CalbaTech also has a molecular applications division, which is developing pathogen microarrays, diagnostics, and electronic-based DNA detection systems, and a division developing cell-based therapies.
Research Triangle Park, NC-based KSE, which is privately held, had revenues in excess of $5.1 million in 2003 and is expected to bring in revenue of more than $6.7 million in 2004, CalbaTech said today. Among the firm's customers are Labcorp, the National Cancer Institute, and Mayo Clinic.